Hoth Therapeutics Inc
Company Profile
Business description
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Contact
1177 Avenue of the Americas
5th Floor, Suite 5066
New YorkNY10036
USAT: +1 646 756-2997
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Finding yield on the ASX
stocks
ExxonMobil earnings: Continued execution, on track for 2030 targets
stocks
Disney earnings: No big surprises in solid results
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.60 | 19.60 | -0.21% |
| CAC 40 | 8,181.17 | 54.64 | 0.67% |
| DAX 40 | 24,797.52 | 258.71 | 1.05% |
| Dow JONES (US) | 49,407.66 | 515.19 | 1.05% |
| FTSE 100 | 10,341.56 | 118.02 | 1.15% |
| HKSE | 26,830.50 | 54.93 | 0.21% |
| NASDAQ | 23,592.11 | 130.29 | 0.56% |
| Nikkei 225 | 54,546.04 | 1,890.86 | 3.59% |
| NZX 50 Index | 13,421.52 | 9.08 | 0.07% |
| S&P 500 | 6,976.44 | 37.41 | 0.54% |
| S&P/ASX 200 | 8,844.70 | 21.60 | -0.24% |
| SSE Composite Index | 4,031.07 | 15.32 | 0.38% |